Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY1 | P47900 | 5/20 | 0.70 |
| ▸ | P2RY2 | P41231 | 3/20 | 0.70 |
| ▸ | GPR17 | Q13304 | 1/20 | 0.49 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.48 |
| ▸ | HTR2C | P28335 | 1/20 | 0.48 |
| ▸ | HTR2B | P41595 | 1/20 | 0.48 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.47 |
| ▸ | NT5E | P21589 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19503299 | 0.99 | P2RY1 (0.69) | P2RY1P2RY2GPR17ADORA3HTR2C | |
| SCHEMBL19503304 | 0.92 | P2RY1 (0.65) | P2RY1P2RY2ADORA3HTR2CHTR2B | |
| SCHEMBL19807533 | 0.89 | P2RY1 (0.58) | P2RY1P2RY2 | |
| SCHEMBL19503300 | 0.87 | P2RY1 (0.67) | P2RY1P2RY2ADORA3ADORA1NT5E | |
| SCHEMBL21257379 | 0.86 | P2RY1 (0.68) | P2RY1P2RY2GPR17ADORA3 | |
| SCHEMBL21257381 | 0.86 | P2RY1 (0.67) | P2RY1P2RY2GPR17ADORA3HTR2C | |
| SCHEMBL19503293 | 0.83 | P2RY1 (1.00) | P2RY1P2RY2ADORA3HTR2CHTR2B | |
| SCHEMBL29318012 | 0.82 | P2RY1 (0.98) | P2RY1P2RY2ADORA3HTR2CHTR2B | |
| SCHEMBL19503344 | 0.81 | ADORA3 (0.64) | P2RY1P2RY2ADORA3HTR2CHTR2B | |
| SCHEMBL21257364 | 0.80 | P2RY1 (0.66) | P2RY1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3445368-B1 | COMPOUNDS AND METHODS FOR TREATING NEUROLOGICAL AND CARDIOVASCULAR CONDITIONS | ASTROCYTE PHARMACEUTICALS INC (US) | 2024-07-17 | — | — | EP | disclosed |
| US-10265338-B2 | Compounds and methods for treating neurological and cardiovascular conditions | ASTROCYTE PHARMACEUTICALS, INC. (US) | 2019-04-23 | — | — | US | disclosed |
| US-20180021363-A1 | COMPOUNDS AND METHODS FOR TREATING NEUROLOGICAL AND CARDIOVASCULAR CONDITIONS | ASTROCYTE PHARMACEUTICALS, INC. | 2018-01-25 | — | — | US | disclosed |
| WO-2017185061-A1 | COMPOUNDS AND METHODS FOR TREATING NEUROLOGICAL AND CARDIOVASCULAR CONDITIONS | ASTROCYTE PHARMACEUTICALS, INC. (US) | 2017-10-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10265338-B2 | Compounds and methods for treating neurological and cardiovascular conditions | TNNI3, CPT1B, TNNT2 | P2RY1 1828/4885P2RY2 1796/4885GPR17 1627/4885 |
| US-20180021363-A1 | COMPOUNDS AND METHODS FOR TREATING NEUROLOGICAL AND CARDIOVASCULAR CONDITIONS | TNNI3, CPT1B, TNNT2 | P2RY1 1828/4885P2RY2 1796/4885GPR17 1627/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.